

## ASX ANNOUNCEMENT

21 November 2022

# Update – Four 20 Pharma and French trial extension



Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) wishes to advise that Four 20 Pharma GmbH (“**Four 20 Pharma**”), which was acquired by Curaleaf Holdings Inc in September 2022, has not satisfied its conditions precedent to secure certain approvals in accordance with their date for satisfaction<sup>1</sup> under its exclusive supply agreement (“**Agreement**”)<sup>2</sup> and has not agreed to extend the date or waive such conditions precedent, meaning the Agreement has now ended. As such, the Company has issued Four 20 Pharma with a notice of default and will also consider offering the high-THC SMS strain into the German market via existing channels.

The Company also wishes to advise the French Government has confirmed it will extend the period of the two-year French medicinal cannabis trial<sup>3</sup> for a further 12 months until March 2024. The Company is currently in negotiations with the Government in relation to their request for the Company’s continued participation given it is the largest supplier into the trial and has been providing products to trial participants free of charge.

**ENDS**  
**BY ORDER OF THE BOARD**

A handwritten signature in black ink, appearing to be "Alistair Warren", written over a horizontal line.

**Alistair Warren**  
Company Secretary

1. Saturday 19 November 2022

2. See ASX release dated 19 May 2022

3. See ASX release dated 27 January 2021



For further information please contact:

**Alistair Warren**  
**Company Secretary**

Little Green Pharma  
E: [a.warren@lgp.global](mailto:a.warren@lgp.global)  
T: +61 8 6280 0050

**Fleta Solomon**  
**Chief Executive Officer**

Little Green Pharma  
E: [f.solomon@lgp.global](mailto:f.solomon@lgp.global)  
T: +61 8 6280 0050

## About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m<sup>2</sup> cultivation and 4,000m<sup>2</sup> GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)